Skip to main content

Advertisement

SpringerLink
Log in

In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To define the most effective combination schedule of paclitaxel and nedaplatin, a new platinum derivative, we investigated the in vitro interaction between these drugs in AZ-521 and NUGC-4 gastric adenocarcinoma and KSE-1 esophageal squamous carcinoma cell lines.

Materials and methods

Cytotoxic activity was determined by the WST-1 assay. Different treatment schedules of the two drugs were compared and evaluated for synergism, additivity, or antagonism using a quantitative method based on the median-effect principle of Chou and Talalay. Cell-cycle perturbation and apoptosis were evaluated by means of flow cytometry.

Results

Upon 24-h sequential exposure, the sequence paclitaxel followed by nedaplatin induced greater than additive effects in all of the cell lines, with synergistic interactions in NUGC-4 and KSE-1 cells. By contrast, antagonistic effects were observed with the reverse sequence. Simultaneous treatment resulted in either a synergistic or antagonistic effect, depending on the cell line. Therefore, the sequence paclitaxel followed by nedaplatin appears most active, at least in these three cell lines. Flow cytometric analyses at IC50 indicated that paclitaxel induced G2/M arrest with subsequent induction of apoptosis (56%) in the sub-G1 phase. When paclitaxel preceded nedaplatin, apoptosis was most prominent (70%) with pronounced G2/M arrest. By contrast, the reverse sequence yielded only 28% induction of apoptotic cells, with almost identical cell-cycle distribution patterns to those observed with nedaplatin alone, indicating that the activity of paclitaxel is abolished by pretreatment with nedaplatin.

Conclusions

Our findings suggest that the interaction of nedaplatin and paclitaxel is highly schedule dependent and that the sequential administration of paclitaxel followed by nedaplatin should be thus incorporated into the design of a clinical trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP (1994) Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086–1091

    CAS  PubMed  Google Scholar 

  2. Alberts DS, Fanta PT, Running KL, Adair LP Jr, Garcia DJ, Liu-Stevens R, Salmon SE (1997) In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers. Cancer Chemother Pharmacol 39:493–497

    Article  CAS  PubMed  Google Scholar 

  3. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55

    Article  CAS  Google Scholar 

  4. Chou TC, Motzer RJ, Tong V, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst (Bethesda) 86:1517–1524

    CAS  Google Scholar 

  5. Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB (1993) In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 92:431–440

    CAS  PubMed  Google Scholar 

  6. Forastiere AA, Shank D, Neuberg D, Taylor SG IV, DeConti RC, Adams G (1998) Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Cancer 82:2270–2274

    Article  CAS  PubMed  Google Scholar 

  7. Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Hara K, Saijo N (1990) Phase II study of (glycolate-O,O’) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26:393–396

    CAS  PubMed  Google Scholar 

  8. Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M, He P (1993) A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull 41:1118

    CAS  Google Scholar 

  9. Inuyama Y, Miyake H, Horiuchi M, Hayasaki K, Komiyama S, Ota K (1992) A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers. Japanese Gan To Kagaku Ryoho 19:871–877

    CAS  Google Scholar 

  10. Kameyama Y, Okazaki N, Nakagawa M, Koshida H, Nakamura M, Gemba M. (1990) Nephrotoxicity of a new platinum compound, 254-S, evaluated with rat kidney cortical slices. Toxicol Lett 52:15–24

    Article  CAS  PubMed  Google Scholar 

  11. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Yazawa Y (1996) In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines. Cancer Chemother Pharmacol 37:525–530

    Article  CAS  PubMed  Google Scholar 

  12. Kobayashi H, Takemura Y, Miyachi H, Ogawa T (1991) Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin. Invest New Drugs 9:313–319

    Article  CAS  PubMed  Google Scholar 

  13. Liebmann JE, Fisher J, Teague D, Cook JA (1994) Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6:25–31

    CAS  PubMed  Google Scholar 

  14. Ma J, Maliepaard M, Nooter K, Boersma AW, Verweij J, Stoter G, Schellens JH (1998) Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother Pharmacol 41:307–316

    Article  CAS  PubMed  Google Scholar 

  15. Matsuoka H, Sugimachi K, Ueo H, Kuwano H, Nakano S, Nakayama M (1987) Sex hormone response of a newly established squamous cell line derived from clinical esophageal carcinoma. Cancer Res 47:4134–4140

    CAS  PubMed  Google Scholar 

  16. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G (1996) Paclitaxel has moderate activity in squamous cervix cancer. a gynecologic oncology group study. J Clin Oncol 14:792–795

    CAS  PubMed  Google Scholar 

  17. Milross CG, Peters LJ, Hunter NR, Mason KA, Milas L (1995) Sequence-dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo. Int J Cancer 62:599–604

    CAS  PubMed  Google Scholar 

  18. Noda K, Ikeda M, Yakushiji M, Nishimura H, Terashima Y, Sasaki H, Hata T, Kuramoto H, Tanaka K, Takahashi T et al (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus. Japanese Gan To Kagaku Ryoho 19:885–892

    CAS  Google Scholar 

  19. Parker RJ, Lee KB, Dabholkar M, Bostick-Bruton F, Simmis M, Reed E (1993) Influence of taxol: cisplatin sequencing on cisplatin-DNA adduct repair in human ovarian cancer cells. Proc Am Assoc Cancer Res 34:356

    Google Scholar 

  20. Rowinsky EK, Citardi MJ, Noe DA, Donehower RC (1993) Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 119:727–733

    Article  CAS  PubMed  Google Scholar 

  21. Sakamoto J, Morita S, Yumiba T, Narahara H, Kinoshita K, Nakane Y, Imamoto H, Shiozaki H (2003) Ascitic Gastric Cancer Study Group of the Japan South West Oncology Group. A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer. Jpn J Clin Oncol 33:238–240

    Article  CAS  PubMed  Google Scholar 

  22. Sekine I, Nishiwaki Y, Watanabe K, Yoneda S, Saijo N (1996) Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res 2:941–945

    CAS  PubMed  Google Scholar 

  23. Sorenson CM, Eastman A (1988) Mechanism of cis-diamminedichloroplatinum (II)-induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer Res 48:4484–4488

    CAS  PubMed  Google Scholar 

  24. Taguchi T, Wakui A, Nabeya K, Kurihara M, Isono K, Kakegawa T, Ota K (1992) A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group. Japanese Gan To Kagaku Ryoho 19:483–488

    CAS  Google Scholar 

  25. Tanaka R, Ariyama H, Qin B, Takii Y, Baba E, Mitsugi K, Harada M, Nakano S (2005) In vitro schedule-dependent interaction between Paclitaxel and Oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol (in press)

  26. Yamada H, Uchida N, Maekawa R, Yoshioka T (2001) Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Cancer Lett 172:17–25

    Article  CAS  PubMed  Google Scholar 

  27. Vanhoefer U, Harstrick A, Wilke H, Schleucher N, Walles H, Schroder J, Seeber S (1995) Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A:92–97

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Department of Internal Medicine and Department of Biosystemic Science of Medicine, Graduate School of Medicine, Kyushu University, 3-1-1 Maidashi, Fukuoka, 812-8582, Japan

    Risa Tanaka, Yasushi Takii, Yoshihiro Shibata, Hiroshi Ariyama, Baoli Qin, Eishi Baba, Hitoshi Kusaba, Kenji Mitsugi, Mine Harada & Shuji Nakano

Authors
  1. Risa Tanaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yasushi Takii
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihiro Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hiroshi Ariyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Baoli Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eishi Baba
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hitoshi Kusaba
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kenji Mitsugi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Mine Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shuji Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shuji Nakano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tanaka, R., Takii, Y., Shibata, Y. et al. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines. Cancer Chemother Pharmacol 56, 279–285 (2005). https://doi.org/10.1007/s00280-004-0991-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-004-0991-y

Keywords

Search

Navigation